The Data from Approval Studies
The original approval studies by the US Food and Drug Administration (FDA) examined over 1,500 men over two years and provide important foundations for understanding side effects. [1] For details on efficacy, see Finasteride: Efficacy & Clinical Studies.
FDA Approval Studies and Initial Findings
The results on sexual side effects showed a surprising picture:
| Side Effect | Finasteride (1 mg) | Placebo | Difference |
|---|---|---|---|
| Decreased Libido | 1.8% | 1.3% | 0.5% |
| Erectile Dysfunction | 1.3% | 0.7% | 0.6% |
| Ejaculation Disorders | 1.2% | 0.7% | 0.5% |
Important: The difference between finasteride and placebo was only 0.5-0.6 percentage points. Even in the placebo group, sexual side effects occurred. This small difference suggests that psychological factors may play a larger role than originally assumed.
A remarkable Italian study systematically investigated this psychological factor with finasteride 5 mg (prostate dose). [2] The study design included 120 men with prostate enlargement divided into two groups: Group A received no information about possible sexual side effects, while Group B was thoroughly informed about them. The results after 12 months were astonishing: For erectile dysfunction, 30.9% of cases occurred in Group B (informed) compared to only 9.6% in Group A (not informed). For decreased libido, it was 23.6% vs. 7.7%, and for ejaculation disorders 16.3% vs. 5.7%. This impressively demonstrates that the expectation of side effects can amplify or even trigger them. The nocebo effect explains why different studies arrive at different rates and underscores the importance of factual, yet non-anxiety-inducing information.
Frequency and Types of Side Effects
The side effects of finasteride are well documented and occur with varying frequencies. The most frequently discussed side effects concern sexual function. Meta-analyses show different results depending on study design: [3] FDA studies report 1.8% compared to 1.3% in the placebo group, while meta-analyses show rates of 5-15% (including nocebo effect) and real-world data show 3-8%. The truth probably lies at 3-5% true medication-related sexual side effects. The higher rates in some studies are partly explainable by the nocebo effect. In most affected individuals, symptoms are mild to moderate, reversible after discontinuation (2-3 months), and often self-limiting, meaning they disappear during treatment.
The temporal course of side effects follows a characteristic pattern. [4] In the first year, side effects typically occur in the first 6-12 months, while from the second year onward, new side effects are rare. After discontinuation, 90-95% of symptoms disappear within 2-3 months. Remarkably, 30-50% of symptoms spontaneously disappear during treatment after 6-12 months, suggesting that the body often adapts to the medication.
An important study investigated effects on sperm parameters and found a slight reduction in sperm count of about 10-15% and a slight reduction in ejaculate volume. [5] However, sperm motility is not significantly impaired. Importantly, all parameters normalize completely 3-6 months after discontinuation. If you have an active desire to conceive, you should discontinue finasteride 2-3 months before planned conception attempts to create optimal conditions for conception.
A rare but documented side effect is gynecomastia (breast enlargement). [6] The frequency ranges from 0.4-1.2% depending on study and dose, mostly occurring with the higher 5 mg dose (prostate treatment). In most cases, gynecomastia is reversible after discontinuation and often occurs asymmetrically, meaning only one side is affected. With topical application (0.005-0.2%), the risk is minimal as systemic exposure is significantly lower and the medication acts primarily locally.
Post-Finasteride Syndrome (PFS)
Post-Finasteride Syndrome describes persistent symptoms after discontinuing finasteride. [7] Some affected individuals report sexual problems, depressive moods, and fatigue that supposedly persist even after discontinuation. However, the study data is unclear, as no large clinical studies have confirmed the syndrome yet. Symptoms are difficult to distinguish from natural aging processes, and estimates of frequency range from 1:5,000 to 1:10,000. [7] This makes it difficult to draw definitive conclusions.
In 2017, Swissmedic introduced a reporting requirement for persistent side effects. [8] In 2025, new warnings regarding psychological side effects, including suicidal ideation, were added. [9]
The agency acknowledges that in rare cases symptoms can persist. However, the scientific evidence for a direct causal relationship is limited.
Topical vs. Oral
The good news is that topical finasteride shows a significantly better side effect profile than oral administration. [11] For a detailed comparison of both forms of administration, read our article Finasteride Topical vs. Oral.
| Side Effect | Topical (0.25%) | Oral (1 mg) |
|---|---|---|
| Sexual Side Effects | 2.8% | 4.8% |
| Serum DHT Reduction | 35% | 55% |
| Systemic Exposure | Minimal | Complete |
With ultra-low dose topical finasteride (0.005%), the side effect rate is even lower since the medication is hardly absorbed into the blood.
Want to stop hair loss and regrow your hair?
Get startedContraindications and Precautions
There are certain situations where finasteride should not be used or special caution is required. Finasteride is absolutely contraindicated in women of childbearing age (pregnancy risk), during pregnancy and breastfeeding, with known hypersensitivity to finasteride, and in children and adolescents under 18 years, as insufficient data exists regarding safety and efficacy.
Special caution is required with active desire to conceive, where finasteride should be discontinued 2-3 months before conception. Caution is also needed with pre-existing sexual dysfunction, severe depression or anxiety disorder, as these conditions could potentially be exacerbated by the medication. With liver insufficiency, dose adjustment may be necessary as finasteride is hepatically metabolized.
Pregnancy and Critical Warning
Finasteride is highly teratogenic for male fetuses. [12] It causes malformations of genital organs in male fetuses, with even skin contact with broken tablets being dangerous. Pregnant women must neither touch nor take finasteride. With topical finasteride, partners and children should not come into contact with treated skin areas.
Risk Minimization with Finasteride
There are various proven approaches to minimize the risk of side effects and improve tolerability. A conscious attitude is central: inform yourself objectively but avoid excessive rumination about possible side effects, as the nocebo effect is real and can amplify symptoms. Keep a symptom diary and discuss concerns with your doctor instead of abruptly discontinuing. If side effects occur, often a dose adjustment alone helps. Your doctor can adjust the dose individually or recommend an alternative form of administration. If discontinuation is necessary, this should be done gradually to avoid a rebound effect.
For risk minimization, topical finasteride is ideal, as at a concentration of 0.005% the medication is hardly absorbed into the blood with virtually no systemic side effects. At 0.2%, absorption is moderate but still associated with significantly fewer side effects than oral administration, making this form of administration an attractive alternative.
Realistic Risk Assessment
To put the numbers in perspective, here's a realistic assessment:
Of 100 men taking 1 mg finasteride orally, 90-95 will have no side effects. 3-5 men will experience mild to moderate sexual side effects that are mostly reversible. 1-2 will discontinue due to side effects, and fewer than 0.02 could develop persistent symptoms (if PFS is real). With topical application (0.005-0.2%), rates are even lower, especially at the lower concentration of 0.005%.
Conclusion for Informed Decision-Making
Finasteride is a well-researched medication with over 25 years of clinical experience. Scientific evidence shows that side effects are relatively rare. True sexual side effects occur in about 3-5% of users. These are mostly mild and reversible, as 90% disappear after discontinuation.
The nocebo effect plays a major role. Anticipatory anxiety demonstrably amplifies symptoms. Topical application further reduces risks (2.8% vs. 4.8% with oral administration). Long-term safety is established with millions of patients over decades.
The decision for or against finasteride should be based on facts, not fear. Topical finasteride offers a safe option with significantly fewer side effects. For more information, see our articles on Finasteride Efficacy & Studies, Finasteride Topical vs. Oral and Finasteride Prescription Switzerland. Start your online consultation now or learn more about hair loss causes.
References
- [1] Kaufman KD, Olsen EA, Whiting D, et al.. (1998). Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology. https://doi.org/10.1016/s0190-9622(98)70007-6
- [2] Mondaini N, Gontero P, Giubilei G, et al.. (2007). Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?. Journal of Sexual Medicine. https://doi.org/10.1111/j.1743-6109.2007.00563.x
- [3] Amory JK, Wang C, Swerdloff RS, et al.. (2007). The Effect of 5α-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2006-2203
- [4] Ramot Y, Czarnowicki T, Zlotogorski A. (2009). Finasteride-induced Gynecomastia: Case Report and Review of the Literature. International Journal of Trichology. https://doi.org/10.4103/0974-7753.51930
- [5] Mysore V. (2012). Finasteride and sexual side effects. Indian Dermatology Online Journal. https://doi.org/10.4103/2229-5178.93496
- [6] Fertig RM, Caresse GA, Darwin E, Gaudi S. (2017). Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: a comprehensive review. Dermatology Online Journal. https://doi.org/10.5070/D32311037240
- [7] Swissmedic. (2017). Finasterid: Persistierende Nebenwirkungen. Swissmedic. https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/pharmacovigilance/vigilance-news/finasterid-persistierende-nebenwirkungen.html (Aufgerufen am 20.09.2025)
- [8] Goodman PJ, Tangen CM, Darke AK, et al.. (2019). Long-Term Effects of Finasteride on Prostate Cancer Mortality. New England Journal of Medicine. https://doi.org/10.1056/NEJMc1809961
- [9] Traish AM. (2020). Post-finasteride syndrome: a surmountable challenge for clinicians. Fertility and Sterility. https://doi.org/10.1016/j.fertnstert.2019.11.030
- [10] Estill MC, Ford A, Omeira R, Rodman M. (2023). Finasteride and Dutasteride for the Treatment of Male Androgenetic Alopecia: A Review of Efficacy and Reproductive Adverse Effects. Georgetown Medical Review. https://doi.org/10.52504/001c.88531
- [11] Hafner J, Läuchli S. (2023). Androgenetische Alopezie: Mehr Therapien für mehr Haare. Rosenfluh Publikationen. https://www.rosenfluh.ch/media/congressselection/2023/02/Androgenetische-Alopezie-Mehr-Therapien-fuer-mehr-Haare.pdf (Aufgerufen am 21.11.2025)
- [12] McQueen P, et al.. (2024). Finasteride delays atherosclerosis progression in mice and is associated with a reduction in plasma cholesterol in men. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2024.100507
- [13] Swissmedic. (2025). DHPC – Finasterid / Dutasterid: Neue Massnahmen zur Minimierung des Risikos für Suizidgedanken. Swissmedic. https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/health-professional-communication--hpc-/dhpc-finasterid-dutasterid.html (Aufgerufen am 21.09.2025)
- [14] MotherToBaby. (1994). Finasteride. Organization of Teratology Information Specialists (OTIS). https://www.ncbi.nlm.nih.gov/books/NBK582707/ (Aufgerufen am 15.09.2025)